Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Authors: Bookman, Michael A | Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology | December 1, 2022 | PubMed abstract
